Hansaitai

Hansaitai is a clinical-stage biopharmaceutical company headquartered in Beijing, China, dedicated to the discovery and development of innovative biologics for autoimmune diseases and inflammatory conditions. The company focuses on the IL-17 signaling pathway, which plays a critical role in the pathogenesis of various chronic inflammatory disorders. Its lead candidate, HST003, is a humanized monoclonal antibody targeting Interleukin-17A that is currently undergoing Phase 2 clinical trials for plaque psoriasis and ankylosing spondylitis. Additionally, the company is advancing HST004, an antibody targeting the Interleukin-17 receptor A, through early-stage clinical development. Hansaitai leverages its proprietary protein engineering platforms to optimize the efficacy and safety profiles of its therapeutic pipeline. By targeting validated pathways with differentiated molecules, the company aims to provide high-quality, accessible treatment options for patients in China and globally.